R+D+i Projects
Research is a fundamental part of our business
Learn about our research projects
As a biotechnology company, at Dreamgenics we carry out different R&D projects with the aim of developing new products and services to offer to our customers.
In the same way, we participate together with hospitals and research centers in projects related to human health in which we put our expertise in NGS data analysis at the service of researchers.
DO YOU HAVE A PROJECT AND NEED A PARTNER? WRITE TO US
This project aims to develop a platform for analysis, integration and visualization of different omics data to overcome the limitations of the isolated whole genome study, so that more valuable information can be obtained from the analysis of different multi-omics data and a broader understanding of the molecular basis of diseases can be achieved.
- Period: 2022-2024
- Financing: 21,101.34 €.
This project aims to understand the molecular basis underlying the response of patients with advanced non-small cell lung cancer (stage III and IV) to treatment with immune checkpoint inhibitors using different omics technologies.
- Period: 2022-2024
- Financing: 70,000 €.
Acquisition of QuantStudio 5 Real-Time PCR Systems equipment
Funding granted "Aid to companies and research centers of the Principality of Asturias to support the transfer of knowledge and technology in the year 2022" managed by FICYT. The purpose of this call is to grant aid to support knowledge and technology transfer actions in the Principality of Asturias in the year 2022 in order to promote and improve the productive and social fabric of the region.
- Period: 2022
- Financing: 26,806.50 €.
Development of a platform for the integration of data resulting from different omics analyses and its implementation in the clinic.
Torres Quevedo grant awarded for the development of a project consisting of obtaining the optimal knowledge, carrying out the necessary research, in order to develop a bioinformatics tool to extract all the clinically relevant information that is possible thanks to the integration of all the data from different omics technologies.
- Period: 2021-2024
- Financing: €52,077
Genetic biomarkers associated with severity in COVID-19.
Project led by the Balearic Islands Health Research Institute Foundation (Idisba) to identify genetic variants associated with severity in COVID-19 that can be used as biomarkers in clinical practice. The role of Dreamgenics in this project is the design of the panel of genes to be studied and the bioinformatics analysis of the data from the sequencing.
- Period: 2020-2021
- Financing: €25,000
Promoting innovation in the early detection of childhood hearing loss in the SUDOE area: Towards personalised medicine based on genomic diagnostic tools.
International genetic study led by the Clínica Universidad de Navarra (CUN) for the diagnosis of hearing loss in newborns. The study involves the participation of 8 entities, including Dreamgenics, from 3 different countries and more than 80 professionals involved. All the members of the team have previous experience in genetic work, diagnosis of hearing loss and early detection.
- Period: 2018-2021
- Financing: €260,000
Bioinformatics platform for the analysis of whole genome sequencing data and its implementation in the clinic.
This project aims to investigate the key aspects that will determine the future development of a bioinformatics tool that is simple and easily interpretable by any physician, regardless of whether or not they have specific training in the emerging field of bioinformatics, and that does not focus solely on the analysis and interpretation of genomic variants in coding regions, as is the case with existing tools.
- Period: 2017-2020
- Financing: 68.905,50 €.
Design of a framework and development of a prototype aimed at the management and bioinformatics exploitation of genomic data from NGS technologies.
Project aimed at designing a framework based on microservices that would offer an independent scaling of existing bioinformatics analysis algorithms and facilitate the development of new algorithms and functionalities. This framework should allow the bioinformatics analysis, exploitation and visualization of genomic and transcriptomic data from next-generation sequencing (NGS) technologies.
- Period: 2017
- Funding: 18.725,88 €.
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance.
This European project consisted of the design of a diagnostic platform, its development and validation, as well as the mutational analysis of patients with chronic lymphocytic leukaemia, developing a new algorithm for the detection of copy number alterations (CNVs) and rearrangements from capture panel sequencing data.
- Period: 2016-2019
- Financing: 104,653.90 €.
We collaborate with
R+D+i Projects
Research is a fundamental part of our business
Research projects
As a biotech company, Dreamgenics is involved in several research projects with the aim of developing new services and products to offer to its customers:
Acquisition of QuantStudio 5 Real-Time PCR Systems equipment
Funding granted "Aid to companies and research centers of the Principality of Asturias to support the transfer of knowledge and technology in the year 2022" managed by FICYT. The purpose of this call is to grant aid to support knowledge and technology transfer actions in the Principality of Asturias in the
year 2022 in order to promote and improve the productive and social fabric of the region.
- Period: 2022
- Financing: 26,806.50 €.
Development of a platform for the integration of data resulting from different omics analyses and its implementation in the clinic.
The aim of this project is to obtain the optimal knowledge, by carrying out the necessary research, in order to develop a bioinformatics tool to extract all the clinically relevant information that is possible thanks to the integration of all the data from different omics technologies.
- Period: 2021-2024
- Financing: €52,077
Genetic biomarkers associated with severity in COVID-19.
Project led by the Balearic Islands Health Research Institute Foundation (Idisba) to identify genetic variants associated with severity in COVID-19 that can be used as biomarkers in clinical practice. The role of Dreamgenics in this project is the design of the panel of genes to be studied and the bioinformatics analysis of the data from the sequencing.
- Period: 2020-2021
- Financing: €25,000
Promoting innovation in the early detection of childhood hearing loss in the SUDOE area: Towards personalised medicine based on genomic diagnostic tools.
International genetic study led by the Clínica Universidad de Navarra (CUN) for the diagnosis of hearing loss in newborns. The study involves the participation of 8 entities, including Dreamgenics, from 3 different countries and more than 80 professionals involved. All the members of the team have previous experience in genetic work, diagnosis of hearing loss and early detection.
- Period: 2018-2021
- Financing: €260,000
Bioinformatics platform for the analysis of whole genome sequencing data and its implementation in the clinic.
This project aims to investigate the key aspects that will determine the future development of a bioinformatics tool that is simple and easily interpretable by any physician, regardless of whether or not they have specific training in the emerging field of bioinformatics, and that does not focus solely on the analysis and interpretation of genomic variants in coding regions, as is the case with existing tools.
- Period: 2017-2020
- Financing: 68.905,50 €.
Design of a framework and development of a prototype aimed at the management and bioinformatics exploitation of genomic data from NGS technologies.
Project aimed at designing a framework based on microservices that would offer an independent scaling of existing bioinformatics analysis algorithms and facilitate the development of new algorithms and functionalities. This framework should allow the bioinformatics analysis, exploitation and visualization of genomic and transcriptomic data from next-generation sequencing (NGS) technologies.
- Period: 2017
- Funding: 18.725,88 €.
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance.
This European project consisted of the design of a diagnostic platform, its development and validation, as well as the mutational analysis of patients with chronic lymphocytic leukaemia, developing a new algorithm for the detection of copy number alterations (CNVs) and rearrangements from capture panel sequencing data.
- Period: 2016-2019
- Financing: 104,653.90 €.
R+D+i Projects
Research is a fundamental part of our business
Research projects
As a biotech company, Dreamgenics is involved in several research projects with the aim of developing new services and products to offer to its customers:
Acquisition of QuantStudio 5 Real-Time PCR Systems equipment
Funding granted "Aid to companies and research centers of the Principality of Asturias to support the transfer of knowledge and technology in the year 2022" managed by FICYT. The purpose of this call is to grant aid to support knowledge and technology transfer actions in the Principality of Asturias in the year 2022 in order to promote and improve the productive and social fabric of the region.
- Period: 2022
- Financing: 26,806.50 €.
Development of a platform for the integration of data resulting from different omics analyses and its implementation in the clinic.
The aim of this project is to obtain the optimal knowledge, by carrying out the necessary research, in order to develop a bioinformatics tool to extract all the clinically relevant information that is possible thanks to the integration of all the data from different omics technologies.
- Period: 2021-2024
- Financing: €52,077
Genetic biomarkers associated with severity in COVID-19.
Project led by the Balearic Islands Health Research Institute Foundation (Idisba) to identify genetic variants associated with severity in COVID-19 that can be used as biomarkers in clinical practice. The role of Dreamgenics in this project is the design of the panel of genes to be studied and the bioinformatics analysis of the data from the sequencing.
- Period: 2020-2021
- Financing: €25,000
Promoting innovation in the early detection of childhood hearing loss in the SUDOE area: Towards personalised medicine based on genomic diagnostic tools.
International genetic study led by the Clínica Universidad de Navarra (CUN) for the diagnosis of hearing loss in newborns. The study involves the participation of 8 entities, including Dreamgenics, from 3 different countries and more than 80 professionals involved. All the members of the team have previous experience in genetic work, diagnosis of hearing loss and early detection.
- Period: 2018-2021
- Financing: €260,000
Bioinformatics platform for the analysis of whole genome sequencing data and its implementation in the clinic.
This project aims to investigate the key aspects that will determine the future development of a bioinformatics tool that is simple and easily interpretable by any physician, regardless of whether or not they have specific training in the emerging field of bioinformatics, and that does not focus solely on the analysis and interpretation of genomic variants in coding regions, as is the case with existing tools.
- Period: 2017-2020
- Financing: 68.905,50 €.
Design of a framework and development of a prototype aimed at the management and bioinformatics exploitation of genomic data from NGS technologies.
Project aimed at designing a framework based on microservices that would offer an independent scaling of existing bioinformatics analysis algorithms and facilitate the development of new algorithms and functionalities. This framework should allow the bioinformatics analysis, exploitation and visualization of genomic and transcriptomic data from next-generation sequencing (NGS) technologies.
- Period: 2017
- Funding: 18.725,88 €.
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance.
This European project consisted of the design of a diagnostic platform, its development and validation, as well as the mutational analysis of patients with chronic lymphocytic leukaemia, developing a new algorithm for the detection of copy number alterations (CNVs) and rearrangements from capture panel sequencing data.
- Period: 2016-2019
- Financing: 104,653.90 €.